article thumbnail

Gene editing: beyond the hype

pharmaphorum

Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. It has also built its own manufacturing site and launched partnerships with six big pharma companies. Zinc fingers are the most common control gene in the body,” Macrae explains. “We

article thumbnail

Scandinavia: insight into opportunities for drug discovery

Drug Discovery World

More so, the Karolinska Institute is ranked at number seven in the world for the subjects of life sciences and medicine. Swedish life sciences industry organisation Lif put the success down to the government’s continued investment in life sciences and the increase in international companies investing in Sweden’s manufacturing sector.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Fibrosis research: Advances and challenges 

Drug Discovery World

PW: Through our exclusive access to one of the world’s largest fibrosis tissue biobanks, we have correlated disease progression to gene expression data, enabling us to discover novel targets on the pathway that drives the advanced stages of fibrotic disease. The gene expression data were generated by RNAseq on biopsies stored at -78°C.

article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

To accelerate drug development timelines, biotechs and pharma companies may choose to outsource some or all parts of antibody discovery and optimisation to DNA synthesis technology partners equipped with the tools and techniques to get reliable results faster. This approach has been around for a while.

DNA 98